Arch Biopartners Inc.

Arch Biopartners Inc. is a therapeutic biotechnology company based in Toronto, Canada, focused on developing novel drugs for acute and chronic kidney diseases, as well as organ damage caused by inflammation and toxins. The company's mission is to address significant unmet medical needs in global kidney care by targeting specific biological drivers of injury.

The company's pipeline centers on the dipeptidase-1 (DPEP1) pathway and includes several drug candidates. Its lead drug candidate, LSALT peptide, is in Phase II clinical trials for cardiac surgery-associated acute kidney injury (CS-AKI). Arch Biopartners is also developing Cilastatin, a repurposed DPEP1 inhibitor, as a treatment for drug toxin-related acute kidney injury, also in Phase II. Additionally, the company is advancing a pre-clinical platform targeting IL-32 for chronic kidney disease, particularly diabetic kidney disease.

Arch Biopartners is a publicly traded company with its shares listed on the TSX Venture Exchange under the symbol ARCH and on the OTCQB market under the symbol ACHFF. Key leadership includes CEO Richard Muruve, CSO Daniel Muruve, and CFO Andrew Bishop. Recent activities include closing non-brokered private placements in March and April 2026, and ongoing patient recruitment and dosing in its Phase II clinical trials for LSALT peptide.